News and Investors
Adynxx is a clinical stage biopharmaceutical company focused on bringing to market novel, disease-modifying products for the treatment of pain and inflammation. Since its founding in 2007, Adynxx has worked to discover and develop transcription factor decoys to modify the course of pain, to collaborate with discovery partners, and to identify in-licensing opportunities with transformative therapeutic profiles to build a pipeline in pain and inflammation.
Data as of May 10, 2021 5:00 PM EDT
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Featured Events & Presentations
More events are coming soon.